Choice of creep or maintenance fluid type and their impact on total daily ICU sodium burden in critically ill patients: A systematic review and meta-analysis - Waskowski, J.; Salvato, S. M.; Muller, M.; Hofer, D.; van Regenmortel, N.; Pfortmueller, C. A. (J Crit Care, 2023)
PURPOSE: Maintenance and hidden/creep fluids are a major source of fluid and sodium intake in intensive care unit (ICU) patients. Recent research indicates that low versus high sodium content maintenance fluids could decrease fluid and sodium burden. We conducted a systematic review (SR) with meta-analysis to summarize the impact of maintenance fluid choice on total daily sodium in ICU patients. MATERIALS AND METHODS: Systematic literature search in Pubmed, Embase, the Cochrane Library and the. CLINICAL TRIALS REGISTRY: Only controlled clinical trials were included. EXCLUSION CRITERIA: trials on resuscitation fluids, performed in the emergency department only and in pediatric patients. Primary objective was the reduction in mean total sodium intake with low versus high sodium content maintenance/creep fluids. RESULTS: Five studies (1105 patients) were included. Heterogeneity was high.Risk of bias was moderate. Mean daily sodium reduction was 117 mmol (95%Confidence Interval [CI] -174; -59; p < 0.001) with low versus high sodium content maintenance/creep fluids. Incidence of hyperchloremia was lower (OR 0.26; 95%CI 0.1; 0.64) with low sodium. There were no differences in the incidences of hyper-/hyponatremia and fluid balances. CONCLUSION: Using low sodium content maintenance/creep fluids substantially reduces daily sodium burden in adult ICU patients. Significant knowledge/research gaps exist regarding relevance and safety. TRIAL REGISTRATION: PROSPERO 2022 CRD42022300577 (February 2022).
Keywords: journalArticle; *Hyponatremia; *Sodium, Dietary; Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton; Adult; Boehringer-Ingelheim, Aseptuva, Astellas, Astra Zeneca, CSL Behring, Novartis,; Child; Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A.,; Covidien, and Nycomed outside the submitted work. The money was paid into; Creep fluids; Critical Illness; Critically ill; Fluid accumulation; GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter,; Humans; Hyperchloremia; Hypernatremia; Intensive Care Units; Lifesciences Services GmbH, Kenta Biotech Ltd., Maquet Critical Care AB, Omnicare; Maintenance fluids; Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Drager AG, Teleflex Medical; Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards; Sodium; authors have nothing to disclose; departmental funds; no personal financial gain applied. NVR has received; speaker's fees and participated in advisory boards organized by Baxter. All other